- Home
- TGTX vs GNTX Comparison
TGTX vs GNTX Comparison
Compare TGTX & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- GNTX
- Stock Information
- Founded
- TGTX 1993
- GNTX 1974
- Country
- TGTX United States
- GNTX United States
- Employees
- TGTX N/A
- GNTX N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- GNTX Auto Parts:O.E.M.
- Sector
- TGTX Health Care
- GNTX Consumer Discretionary
- Exchange
- TGTX Nasdaq
- GNTX Nasdaq
- Market Cap
- TGTX 4.2B
- GNTX 4.8B
- IPO Year
- TGTX 1995
- GNTX N/A
- Fundamental
- Price
- TGTX $29.45
- GNTX $28.16
- Analyst Decision
- TGTX Strong Buy
- GNTX Buy
- Analyst Count
- TGTX 4
- GNTX 7
- Target Price
- TGTX $42.50
- GNTX $29.14
- AVG Volume (30 Days)
- TGTX 2.9M
- GNTX 2.2M
- Earning Date
- TGTX 08-04-2025
- GNTX 07-25-2025
- Dividend Yield
- TGTX N/A
- GNTX 1.71%
- EPS Growth
- TGTX N/A
- GNTX N/A
- EPS
- TGTX 0.36
- GNTX 1.77
- Revenue
- TGTX $454,069,000.00
- GNTX $2,384,794,644.00
- Revenue This Year
- TGTX $84.00
- GNTX $9.67
- Revenue Next Year
- TGTX $39.26
- GNTX $5.83
- P/E Ratio
- TGTX $81.62
- GNTX $15.84
- Revenue Growth
- TGTX 30.96
- GNTX 2.43
- 52 Week Low
- TGTX $21.11
- GNTX $20.28
- 52 Week High
- TGTX $46.48
- GNTX $31.75
- Technical
- Relative Strength Index (RSI)
- TGTX 42.03
- GNTX 68.84
- Support Level
- TGTX $27.23
- GNTX $27.09
- Resistance Level
- TGTX $28.85
- GNTX $27.91
- Average True Range (ATR)
- TGTX 1.11
- GNTX 0.49
- MACD
- TGTX 0.29
- GNTX -0.06
- Stochastic Oscillator
- TGTX 99.05
- GNTX 98.97
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.